TY - JOUR T1 - Seroprevalence of the SARS-CoV-2 infection in health workers of the Sanitary Region VIII, at province of Buenos Aires JF - medRxiv DO - 10.1101/2020.09.07.20189050 SP - 2020.09.07.20189050 AU - Andrea P. Silva AU - M. Fernanda Aguirre AU - Christian Ballejo AU - M. Jimena Marro AU - Andrea V. Gamarnik AU - Gastón Vargas AU - Marina Pifano AU - Teresa B. Varela AU - Enio García AU - Alicia EB Lawrynowicz AU - Osvaldo C. Uez AU - Irene Pagano Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/09/2020.09.07.20189050.abstract N2 - Introduction The aim of this study was to estimate the seroprevalence of the SARS-CoV-2 infection in health workers of the Sanitary Region VIII, at province of Buenos Aires during June 2020.Methods A cross-sectional design was used. A probabilistic sampling by two-stage conglomerates was carried out. Data were collected from a self-administered questionnaire and a blood sample for antibody identification. The COVIDAR IgG and IgM test were used. RESULTS: 738 health workers were included; the overall response rate was 73.80%. 71.83% of that were women; age showed a normal distribution. Nurses and doctors accounted for more than half of the staff. 75.86% of people claimed to always use Personal Protective Equipment. 5.61% of people had close contact with a confirmed case of COVID-19. 4.60% of people had previously had a nasopharyngeal swab with a negative result. Five workers had positive IgG for SARS-CoV-2 (four women and one man) with negative IgM. The mean age of the cases was 35 years old; two of them were asymptomatic; neither of them had a swab sample taken. The overall seroprevalence was 0.75%, with no significant differences between strata.Discussion The seroprevalence found was low; indicating a large proportion of workers was susceptible to infection. We stress the need to complement passive epidemiological surveillance strategies with serological monitoring in health workers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external financing was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The investigation initiative was approved by the INE Research Ethics Committee registered under code CE00264 in the National Registry of Health Research (RENIS, by its acronym in Spanish) authorized by the Central Ethics Committee no. 059/2019.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData not available ER -